Biogen Idec prepares employment drive for new production plant  

2005.02.16
Biogen Idec is preparing to recruit managerial and other key staff for its production plant in Hillerød, north of Copenhagen, which is currently under construction

Biogen Idec is preparing to recruit managerial and other key staff for its production plant in Hillerød, north of Copenhagen, which is currently under construction. Biogen Idec's plant is its first production facility outside the US, and is expected to produce the company's promising drug Tysabri for the treatment of multiple sclerosis from 2008. The drug was approved by FDA in November 2004 and is waiting for approval from the European Health Authorities.

 

The construction of the new factory in Hillerød has previously been reported to have a budget around DKK 2 bn (USD 320 mn), and a total of 350 new jobs are expected to be created.

 

Biogen Idec is headquartered in Cambridge, MA, employs 4,000 people in 21 countries and is the world's third largest biotech company. In 2003, it generated revenues of DKK 10.3 bn (USD 1.8 bn). Biogen Idec concentrates its research on neurology, cancer and dermatology.

 

Link > Biogen Idec 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×